Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Daratumumab”

362 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 362 results

Testing effectiveness (Phase 2)Study completedNCT02336815
What this trial is testing

Selinexor Treatment of Refractory Myeloma

Who this might be right for
Multiple Myeloma
Karyopharm Therapeutics Inc 202
Large-scale testing (Phase 3)Not Yet RecruitingNCT07740486
What this trial is testing

A Study Comparing Treatment With Teclistamab and Talquetamab Versus Daratumumab and Lenalidomide in Patients With Multiple Myeloma After Stem Cell Transplant Who Still Have Detectable Disease

Who this might be right for
Multiple Myeloma (MM)
Polish Myeloma Consortium 248
Testing effectiveness (Phase 2)Looking for participantsNCT07362199
What this trial is testing

Anti-CD38 Monoclonal Antibody Combined With Rituximab in the Management of Primary Immune Thrombocytopenia (ITP)

Who this might be right for
Immune ThrombocytopeniaTreatment
Institute of Hematology & Blood Diseases Hospital, China 20
Testing effectiveness (Phase 2)WithdrawnNCT06046287
What this trial is testing

Daratumumab for Polyneuropathy Associated With MGUS

Who this might be right for
Peripheral NeuropathyMonoclonal Gammopathy of Undetermined Significance
Georgetown University
Post-approval studies (Phase 4)Study completedNCT05511428
What this trial is testing

Home Based Daratumumab Administration for Patients With Multiple Myeloma

Who this might be right for
Plasma Cell Myeloma
Thomas Jefferson University 20
Early research (Phase 1)Active Not RecruitingNCT04108195
What this trial is testing

Subcutaneous Daratumumab Regimens in Combination With Bispecific T Cell Redirection Antibodies for the Treatment of Participants With Multiple Myeloma

Who this might be right for
Multiple Myeloma
Janssen Research & Development, LLC 290
Early research (Phase 1)Ended earlyNCT04892264
What this trial is testing

Belantamab Mafodotin, Lenalidomide, and Daratumumab for the Treatment of Relapsed, Refractory, or Previously Untreated Multiple Myeloma

Who this might be right for
Plasma Cell MyelomaRecurrent Plasma Cell MyelomaRefractory Plasma Cell Myeloma
Mayo Clinic 5
Early research (Phase 1)WithdrawnNCT04466475
What this trial is testing

Radioimmunotherapy (211At-OKT10-B10) and Chemotherapy (Melphalan) Before Stem Cell Transplantation for the Treatment of Multiple Myeloma

Who this might be right for
Plasma Cell Myeloma
Fred Hutchinson Cancer Center
Testing effectiveness (Phase 2)Active Not RecruitingNCT03500445
What this trial is testing

Daratumumab, Carfilzomib, Lenalidomide and Low Dose Dexamethasone (DKRd) in Newly Diagnosed, Multiple Myeloma

Who this might be right for
MyelomaMultiple Myeloma
University of Chicago 75
Testing effectiveness (Phase 2)Looking for participantsNCT06418477
What this trial is testing

Daratumumab, Bortezomib, Cyclophosphamide, and Dexamethasone Therapy for Patients with MIDD

Who this might be right for
Monoclonal Gammopathy of Renal Significance
Peking University People's Hospital 20
Large-scale testing (Phase 3)Study completedNCT03275285
What this trial is testing

Multinational Clinical Study Comparing Isatuximab, Carfilzomib And Dexamethasone To Carfilzomib And Dexamethasone In Relapse And/Or Refractory Multiple Myeloma Patients

Who this might be right for
Plasma Cell Myeloma
Sanofi 302
Not applicableUnknownNCT06455748
What this trial is testing

Daratumumab/Daratumumab and Hyaluronidase-fihj in Combination With Pomalidomide and Dexamethasone for the Treatment of Patients With Newly Diagnosed AL Amyloidosis: a Prospective, Multicenter, Single-arm Study

Who this might be right for
Amyloid Light-chain Amyloidosis
Yongyong MA 20
Testing effectiveness (Phase 2)Study completedNCT03023423
What this trial is testing

Daratumumab in Combination With Atezolizumab Compared With Atezolizumab Alone in Participants With Previously Treated Advanced or Metastatic Non-Small Cell Lung Cancer

Who this might be right for
Carcinoma, Non-Small-Cell Lung
Janssen Research & Development, LLC 100
Testing effectiveness (Phase 2)WithdrawnNCT05408026
What this trial is testing

Study of Combination POM, BTZ, Low-Dose DEX, and DARA (PVD-DARA) in Patients With RRMM

Who this might be right for
Relapsed or Refractory Multiple Myeloma
Alliance Foundation Trials, LLC.
Early research (Phase 1)Study completedNCT01998971
What this trial is testing

JNJ-54767414 (HuMax CD38) (Anti-CD38 Monoclonal Antibody) in Combination With Backbone Treatments for the Treatment of Patients With Multiple Myeloma

Who this might be right for
Multiple Myeloma
Janssen Research & Development, LLC 240
Testing effectiveness (Phase 2)Looking for participantsNCT04915248
What this trial is testing

Study to Evaluate Combined Treatment of Daratumumab, Bortezomib and Dexamethasone in PBL Patients.

Who this might be right for
Plasmablastic Lymphoma
Fondazione Italiana Linfomi - ETS 28
Testing effectiveness (Phase 2)Looking for participantsNCT07485647
What this trial is testing

Identifying Effective and Cost-Conscious Maintenance Daratumumab Dosing

Who this might be right for
Multiple Myeloma
Eden Biltibo 50
Testing effectiveness (Phase 2)Looking for participantsNCT06892522
What this trial is testing

Assess Change in Disease Activity and Adverse Events (AE)s in Adult Participants With Multiple Myeloma Receiving T Cell Engaging Bi/Tri-specific Antibodies Intravenously (IV)/Subcutaneously (SC) Alone or in Combinations

Who this might be right for
Multiple Myeloma
AbbVie 602
Not applicableUnknownNCT05088330
What this trial is testing

Access of Daratumumab Combined With VRD in the Treatment of Patients With Standard-risk Newly Diagnosed MM

Who this might be right for
Newly Diagnosed Multiple Myeloma
The First Affiliated Hospital of Soochow University 76
Not applicableStudy completedNCT05284591
What this trial is testing

Non-interventional Study to Evaluate Patient and Healthcare Provider Satisfaction of Daratumumab Use in the Treatment of First-line Daratumumab, Lenalidomide, Dexamethasone (DRd) Multiple Myeloma Patients in Germany Depending on Application Route (sc or iv)

Who this might be right for
Multiple MyelomaNewly DiagnosedTransplant Ineligible+3 more
iOMEDICO AG 96
Next Page